Polaris Pharmacy Services Adds UPLIZNA® (inebilizumab-cdon) to Rare Disease Portfolio

You are currently viewing Polaris Pharmacy Services Adds UPLIZNA® (inebilizumab-cdon) to Rare Disease Portfolio

BALDWIN PARK, California, October 26, 2021 – Access for UPLIZNA® (inebilizumab-cdon) is now available for eligible patients at Polaris Pharmacy Services. UPLIZNA is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

NMOSD is a rare neuroinflammatory autoimmune disease characterized by unpredictable attacks that often lead to a severe, irreparable disability including loss of vision, paralysis, loss of sensation, bladder and bowel dysfunction, nerve pain, and respiratory failure. Each NMOSD attack can lead to further damage and disability.

“Our mantra at Polaris is to “do everything for every patient every day.” We’re honored that Horizon has extended their trust to the Polaris team and that we will now be able to provide care for patients prescribed UPLIZNA in the comfort of their own homes,” said Stephen Samuel, CEO, Polaris Pharmacy Services. Polaris Pharmacy’s onsite licensed home health agency promotes fluid home-based services with integration and coordination among providers.

About Polaris Pharmacy Services

Polaris Pharmacy Services is a URAC accredited specialty pharmacy with a rare disease center of excellence distinction serving patients nationwide. Polaris is headquartered in Baldwin Park, California, with additional locations in Missouri, Pennsylvania, and New Jersey. With over 600 team members working around the clock 365 days a year to serve patients, Polaris ensures the best clinical outcomes by building customized programs around patients and their individual disease states. They are known for their ability to quickly gain access to challenging patients and products. With a unique approach designed for orphan, rare disease, oral oncology, specialty infusion, and limited distribution products, Polaris provides the high-touch specialty therapy management pharma and biotech manufacturers need and appreciate.

For more information on Polaris, visit: https://premierpharmacyservices.com/. Contact: Andrew Hogenson at 626-626-9426.

For more information about the symptoms, diagnosis, and treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD), please visit UPLIZNA.com or call 1-833-842-8477.